Jackson Kenneth C, Sheng Xiaoming, Nelson Richard E, Keskinaslan Abdulkadir, Brixner Diana I
Clin Ther. 2008 Aug;30(8):1558-63. doi: 10.1016/j.clinthera.2008.08.010.
The aim of this analysis was to assess the impact of multiple combination therapies on medication possession ratios (MPRs) in an antihypertensive naive population.
Data were collected using the Integrated Healthcare Information Solution's National Benchmark Database (January 1997 to June 2004). Data from patients who received 2-pill pharmacotherapy with valsartan or valsartan/hydrochlorothiazide (HCTZ) in a fixed-dose combination (FDC) + amlodipine were compared with those from patients who received 3-pill therapy with valsartan + HCTZ + amlodipine as 3 free-drug components. MPR was calculated by dividing the total days' supply for the lower value in the case of individual drug components, or the number of days' supply in the case of FDC, by 365 (the number of days during the 1-year study period the medication regimen was prescribed). A general linear regression was then performed to determine the effect of treatment group on MPR, controlling for the demographic and clinical characteristics.
Data from 908 patients were included (527 women, 381 men; mean age, 53.9 years; 2-pill treatment with valsartan + amlodipine, 224 patients; 2-pill treatment with valsartan/HCTZ + amlodipine, 619; and 3-pill therapy with valsartan + HCTZ + amlodipine, 65). The MPR values were 75.4%, 73.1%, and 60.5%, respectively (P = 0.005). MPR improved with age (69.6% in the subset aged 18-<36 years vs 75.2% in the subset aged >or=64 years; P = 0.023).
In these antihypertensive-naive patients with hypertension, MPR decreased with the increase in tablets per regimen, and improved MPR was correlated with increasing age. These findings suggest patient compliance improves with simplified pharmacotherapeutic approaches.
本分析旨在评估多种联合疗法对初治高血压人群药物持有率(MPR)的影响。
使用综合医疗信息解决方案的国家基准数据库(1997年1月至2004年6月)收集数据。将接受缬沙坦或缬沙坦/氢氯噻嗪(HCTZ)固定剂量复方(FDC)+氨氯地平两联药物治疗的患者数据与接受缬沙坦+HCTZ+氨氯地平三联药物治疗(三种游离药物成分)的患者数据进行比较。MPR的计算方法是,在单个药物成分的情况下,用供应天数较低值的总天数除以365(1年研究期间规定药物治疗方案的天数);在FDC的情况下,用供应天数除以365。然后进行一般线性回归,以确定治疗组对MPR的影响,并对人口统计学和临床特征进行控制。
纳入908例患者的数据(527例女性,381例男性;平均年龄53.9岁;缬沙坦+氨氯地平两联治疗,224例患者;缬沙坦/HCTZ+氨氯地平两联治疗,619例;缬沙坦+HCTZ+氨氯地平三联治疗,65例)。MPR值分别为75.4%、73.1%和60.5%(P = 0.005)。MPR随年龄增长而改善(18至<36岁亚组为69.6%,≥64岁亚组为75.2%;P = 0.023)。
在这些初治高血压患者中,MPR随每种治疗方案片剂数量的增加而降低,且改善的MPR与年龄增长相关。这些发现表明,简化药物治疗方法可提高患者依从性。